RecruitingPhase 3NCT04597294

Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence

A Randomized, Multicenter Clinical Trial Comparing the Combination of Perioperative FLOT Chemotherapy and Preoperative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Plus Gastrectomy to Perioperative FLOT Chemotherapy and Gastrectomy Alone in Patients With Advanced Gastric Cancer at High Risk of Peritoneal Recurrence


Sponsor

Jagiellonian University

Enrollment

600 participants

Start Date

Aug 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The study was designed to evaluate the efficacy of perioperative FLOT chemotherapy in combination with perioperative hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer at high risk of peritoneal metastases. The impact of treatment on peritoneal recurrence and survival over 6 months, 1, 3 and 5 years will be assessed.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

  • Gastric cancer confirmed histopathologically in tumor specimens.
  • Age 18-75 years.
  • Advanced gastric cancer cT3 / cT4a / N0-3b.
  • No distant metastases on computed tomography (CT) scan of the chest, abdomen and pelvis (cM0).
  • Written consent to participate in the study.

Exclusion Criteria10

  • No clear histopathological confirmation of gastric cancer.
  • Age \> 75 years.
  • Poor general condition (Performance Status 3 or more on the Eastern Cooperative Oncology Group (ECOG)/World Health Organization scale).
  • Previous abdominal surgery (including oncological surgery), other than laparoscopic cholecystectomy or appendectomy (open or laparoscopic).
  • Pregnancy and lactation.
  • Refusal to participate or an inability to provide written consent.
  • Coexisting cancer in another location.
  • Systemic treatment or radiotherapy for another cancer.
  • Dysphagia requiring surgical treatment (gastric resection or nutritional jejunostomy) before starting neoadjuvant treatment and indication for accelerated surgery for other reasons.
  • Disqualification for perioperative FLOT4 chemotherapy as decided by a multi-specialist consultation.

Interventions

COMBINATION_PRODUCTFLOT + HIPEC + Surgery

HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy

COMBINATION_PRODUCTFLOT + Surgery

Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery


Locations(1)

Department of General, Oncological, Gastroenterological Surgery and Transplantology

Krakow, Lesser Poland Voivodship, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04597294


Related Trials